NR1H4 and metabolic dysfunction-associated steatohepatitis: We found that DSF modulated the gut microbial diversity, directly inhibited the growth of Clostridium and reduced Clostridium-mediated 7α-dehydroxylation activity to suppress secondary bile acid biosynthesis, which in turn activated hepatic FXR signaling to finally ameliorate NASH.